Literature DB >> 9337448

Melatonin: therapeutic use in sleep disorders.

J E Chase1, B E Gidal.   

Abstract

OBJECTIVE: To review the use of melatonin in sleep disorders, including jet lag, shift work disorder, insomnia, and sleep cycle disorders in neurologically impaired patients. DATA SOURCE: A MEDLINE search (1966 to April 1996) was performed that included clinical studies and reviews on melatonin in the English language. References used in those articles were also screened for additional information. STUDY SELECTION: All published trials were considered for inclusion in this review, with an emphasis placed on more recently published studies (last 5 years). DATA SYNTHESIS: There is significant evidence that links the hormone melatonin to circadian sleep cycles in humans. It has been suggested that in situations where the endogenous melatonin concentration is reduced (advancing age) or the normal circadian cycle is disrupted (jet lag, shift work, blind patients), supplementation with exogenous melatonin may improve both sleep duration and quality. Limited data from generally short-term trials and anecdotal reports suggest that melatonin may be effective in several of these sleep disorders. Melatonin use in jet lag appears to decrease jet lag symptoms and hasten the return to normal energy levels. Melatonin may be helpful in rotating shift schedules to improve sleep quality and maintain normal circadian rhythm. In some patients with insomnia, melatonin appears to induce sleep onset. The optimal dosage and timing of drug administration is still unclear.
CONCLUSIONS: Although there is some evidence that melatonin may have modest efficacy, especially in insomnia, jet lag, and sleep disorders in neurologically impaired patients, adequate long-term studies examining both efficacy and toxicity are lacking. In addition, further studies evaluating dose-response relationships and drug interactions are warranted.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9337448     DOI: 10.1177/106002809703101015

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  8 in total

1.  Melatonin for treatment of sleeping disorders in children with attention deficit/hyperactivity disorder: a preliminary open label study.

Authors:  Cecil V Tjon Pian Gi; Joris P A Broeren; J Sander Starreveld; Florens G A Versteegh
Journal:  Eur J Pediatr       Date:  2003-06-03       Impact factor: 3.183

Review 2.  Sleep disorders in the elderly.

Authors:  R Asplund
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

Review 3.  Medication for sleep-wake disorders.

Authors:  G Stores
Journal:  Arch Dis Child       Date:  2003-10       Impact factor: 3.791

Review 4.  Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis.

Authors:  Nina Buscemi; Ben Vandermeer; Nicola Hooton; Rena Pandya; Lisa Tjosvold; Lisa Hartling; Sunita Vohra; Terry P Klassen; Glen Baker
Journal:  BMJ       Date:  2006-02-10

5.  Screening of sleep assisting drug candidates with a Drosophila model.

Authors:  Yan-Ying Wang; Wei-Wei Ma; I-Feng Peng
Journal:  PLoS One       Date:  2020-07-29       Impact factor: 3.240

6.  Comparative effectiveness and safety of pharmacological and non-pharmacological interventions for insomnia: an overview of reviews.

Authors:  Patricia Rios; Roberta Cardoso; Deanna Morra; Vera Nincic; Zahra Goodarzi; Bechara Farah; Sharada Harricharan; Charles M Morin; Judith Leech; Sharon E Straus; Andrea C Tricco
Journal:  Syst Rev       Date:  2019-11-15

Review 7.  Homo sapiens May Incorporate Daily Acute Cycles of "Conditioning-Deconditioning" to Maintain Musculoskeletal Integrity: Need to Integrate with Biological Clocks and Circadian Rhythm Mediators.

Authors:  David A Hart; Ronald F Zernicke; Nigel G Shrive
Journal:  Int J Mol Sci       Date:  2022-09-01       Impact factor: 6.208

8.  Long-term melatonin treatment for the sleep problems and aberrant behaviors of children with neurodevelopmental disorders.

Authors:  Kotaro Yuge; Shinichiro Nagamitsu; Yuko Ishikawa; Izumi Hamada; Hiroyuki Takahashi; Hideyuki Sugioka; Osamu Yotsuya; Kazuo Mishima; Masaharu Hayashi; Yushiro Yamashita
Journal:  BMC Psychiatry       Date:  2020-09-10       Impact factor: 3.630

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.